JP2011520098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520098A5 JP2011520098A5 JP2011505224A JP2011505224A JP2011520098A5 JP 2011520098 A5 JP2011520098 A5 JP 2011520098A5 JP 2011505224 A JP2011505224 A JP 2011505224A JP 2011505224 A JP2011505224 A JP 2011505224A JP 2011520098 A5 JP2011520098 A5 JP 2011520098A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- macers
- time point
- level
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 34
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 19
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 19
- 239000000692 natriuretic peptide Substances 0.000 claims description 19
- 230000002411 adverse Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 2
- 102400001263 NT-proBNP Human genes 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 102000046255 Type III Sodium-Phosphate Cotransporter Proteins Human genes 0.000 claims description 2
- 108091006286 Type III sodium-phosphate co-transporters Proteins 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 231100000225 lethality Toxicity 0.000 claims description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 235000009421 Myristica fragrans Nutrition 0.000 claims 2
- 239000001115 mace Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4615808P | 2008-04-18 | 2008-04-18 | |
| US61/046,158 | 2008-04-18 | ||
| PCT/US2009/040941 WO2009129454A2 (en) | 2008-04-18 | 2009-04-17 | Predicting risk of major adverse cardiac events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014082442A Division JP5873521B2 (ja) | 2008-04-18 | 2014-04-14 | 主要有害心イベントのリスクを予測する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520098A JP2011520098A (ja) | 2011-07-14 |
| JP2011520098A5 true JP2011520098A5 (enExample) | 2012-12-27 |
| JP5526122B2 JP5526122B2 (ja) | 2014-06-18 |
Family
ID=41199760
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505224A Expired - Fee Related JP5526122B2 (ja) | 2008-04-18 | 2009-04-17 | 主要有害心イベントのリスクを予測する方法 |
| JP2014082442A Expired - Fee Related JP5873521B2 (ja) | 2008-04-18 | 2014-04-14 | 主要有害心イベントのリスクを予測する方法 |
| JP2016006007A Expired - Fee Related JP6200975B2 (ja) | 2008-04-18 | 2016-01-15 | 主要有害心イベントのリスクを予測する方法 |
| JP2017162932A Expired - Fee Related JP6484679B2 (ja) | 2008-04-18 | 2017-08-28 | 主要有害心イベントのリスクを予測する方法 |
| JP2019026401A Expired - Fee Related JP6788050B2 (ja) | 2008-04-18 | 2019-02-18 | 主要有害心イベントのリスクを予測する方法 |
| JP2020181010A Ceased JP2021039108A (ja) | 2008-04-18 | 2020-10-29 | 主要有害心イベントのリスクを予測する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014082442A Expired - Fee Related JP5873521B2 (ja) | 2008-04-18 | 2014-04-14 | 主要有害心イベントのリスクを予測する方法 |
| JP2016006007A Expired - Fee Related JP6200975B2 (ja) | 2008-04-18 | 2016-01-15 | 主要有害心イベントのリスクを予測する方法 |
| JP2017162932A Expired - Fee Related JP6484679B2 (ja) | 2008-04-18 | 2017-08-28 | 主要有害心イベントのリスクを予測する方法 |
| JP2019026401A Expired - Fee Related JP6788050B2 (ja) | 2008-04-18 | 2019-02-18 | 主要有害心イベントのリスクを予測する方法 |
| JP2020181010A Ceased JP2021039108A (ja) | 2008-04-18 | 2020-10-29 | 主要有害心イベントのリスクを予測する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8090562B2 (enExample) |
| EP (5) | EP3093663B1 (enExample) |
| JP (6) | JP5526122B2 (enExample) |
| AU (3) | AU2009236109B2 (enExample) |
| CA (1) | CA2720674A1 (enExample) |
| DK (4) | DK2269063T3 (enExample) |
| ES (4) | ES2590213T3 (enExample) |
| HR (2) | HRP20131100T1 (enExample) |
| HU (2) | HUE029880T2 (enExample) |
| PL (4) | PL3093663T3 (enExample) |
| PT (4) | PT2827152T (enExample) |
| SI (4) | SI2660599T1 (enExample) |
| WO (1) | WO2009129454A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| WO2003094856A2 (en) | 2002-05-09 | 2003-11-20 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
| WO2007127749A2 (en) | 2006-04-24 | 2007-11-08 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| US20090305265A1 (en) * | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PL2021796T3 (pl) | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| HUE025058T2 (en) * | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
| US9968266B2 (en) | 2006-12-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Risk stratification based heart failure detection algorithm |
| HUE029880T2 (en) | 2008-04-18 | 2017-04-28 | Critical Care Diagnostics Inc | Predicting the risk of serious heart events |
| ES2795003T3 (es) * | 2008-10-07 | 2020-11-20 | Brahms Gmbh | Biomarcador para la predicción de los primeros eventos adversos |
| US9561006B2 (en) * | 2008-10-15 | 2017-02-07 | The United States Of America As Represented By The Secretary Of The Navy | Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival |
| US8417541B1 (en) * | 2009-08-27 | 2013-04-09 | Cerner Innovation, Inc. | Multi-stage model for predicting probabilities of mortality in adult critically ill patients |
| US20130066212A1 (en) * | 2009-09-25 | 2013-03-14 | Volcano Corporation | Device and Method for Determining the Likelihood of a Patient Having a Clinical Event or a Clinically Silent Event Based on Ascertained Physiological Parameters |
| EP3434694B1 (en) | 2010-04-09 | 2020-12-30 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| US10943676B2 (en) | 2010-06-08 | 2021-03-09 | Cerner Innovation, Inc. | Healthcare information technology system for predicting or preventing readmissions |
| CN103718046B (zh) * | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| EP2734222B1 (en) | 2011-07-18 | 2016-10-19 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| CN104507383B (zh) | 2012-05-18 | 2018-08-28 | 重症监护诊断股份有限公司 | 用于治疗或预报室性快速性心律失常事件风险的方法 |
| CN102830234A (zh) * | 2012-08-10 | 2012-12-19 | 杭州华得森生物技术有限公司 | 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒 |
| CN104737023B (zh) | 2012-08-16 | 2017-07-28 | 重症监护诊断股份有限公司 | 预测患高血压风险的方法 |
| JP6450679B2 (ja) | 2012-08-21 | 2019-01-09 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | マルチマーカーリスク層別化 |
| RU2510505C1 (ru) * | 2012-11-15 | 2014-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда |
| GB201310290D0 (en) * | 2013-06-10 | 2013-07-24 | Univ Manchester | Method for determining a probability of a major adverse cardiac event (MACE) |
| JP6655016B2 (ja) * | 2014-01-10 | 2020-02-26 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心不全のリスクを決定するための方法 |
| AU2014407088B2 (en) | 2014-09-26 | 2021-09-23 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| WO2016140958A1 (en) * | 2015-03-02 | 2016-09-09 | Estes Edward Harvey | Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score |
| EP4442200A3 (en) | 2016-04-01 | 2024-12-04 | Cardiac Pacemakers, Inc. | Multi-disease patient management |
| AT518560B1 (de) | 2016-04-18 | 2018-01-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegebalken für eine Schwenkbiegemaschine |
| EP4445834A3 (en) | 2017-04-29 | 2024-12-25 | Cardiac Pacemakers, Inc. | Heart failure event rate assessment |
| US20200074313A1 (en) * | 2018-08-29 | 2020-03-05 | Koninklijke Philips N.V. | Determining features to be included in a risk assessment instrument |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| EP4640848A2 (en) | 2019-05-17 | 2025-10-29 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| US11551817B2 (en) | 2020-01-14 | 2023-01-10 | International Business Machines Corporation | Assessing unreliability of clinical risk prediction |
| CN117099000A (zh) * | 2021-03-08 | 2023-11-21 | 赛诺菲 | 心血管疾病 |
| WO2023086746A1 (en) * | 2021-11-11 | 2023-05-19 | Beckman Coulter, Inc. | Assessment of risk for major adverse cardiac event |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
| US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
| JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体 |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| JP2732005B2 (ja) | 1992-12-14 | 1998-03-25 | 眞一 富永 | ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法 |
| JPH0731479A (ja) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法 |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| JP2001500724A (ja) | 1996-08-23 | 2001-01-23 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | Ｔ１レセプター様リガンドｉｉ |
| WO1998038311A1 (en) | 1997-02-28 | 1998-09-03 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
| DE19711932A1 (de) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms |
| EP1003501B9 (en) | 1997-04-02 | 2005-06-08 | The Brigham And Women's Hospital, Inc. | Use of an agent for lowering the risk of cardiovascular disease |
| CA2293718A1 (en) | 1997-06-10 | 1998-12-17 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| DE69833118T2 (de) | 1997-09-11 | 2006-08-31 | Shionogi & Co., Ltd. | Immunoassay zum bestimmen von bnp |
| GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| GB9827348D0 (en) * | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
| WO2000035473A2 (en) | 1998-12-18 | 2000-06-22 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
| AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| FR2795823B1 (fr) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
| AU783855B2 (en) | 1999-08-24 | 2005-12-15 | Medicure International Inc. | Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| FR2807170B1 (fr) | 2000-03-30 | 2002-06-28 | Sipal | Charniere elastique a frottement reduit |
| RU2002110275A (ru) | 2000-08-22 | 2004-03-27 | Дзе Брихэм Энд Уимен'З Хоспитал, Инк. (Us) | Диагностика и лечение сердечно-сосудистых состояний |
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
| FI20010019A7 (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen gastriitin diagnostisoimiseksi |
| US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
| US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
| WO2003094856A2 (en) | 2002-05-09 | 2003-11-20 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
| WO2003100000A2 (en) | 2002-05-24 | 2003-12-04 | Tularik Inc. | Amplification and overexpression of oncogenes |
| US8263325B2 (en) | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
| AU2003302132B2 (en) * | 2002-11-21 | 2008-02-21 | Inverness Medical Switzerland Gmbh | Bodily fluid markers of tissue hypoxia |
| US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
| US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
| US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| US20060257558A1 (en) | 2003-10-31 | 2006-11-16 | Hiroshi Nomura | Plasma polymerization of atomically modified surfaces |
| EP2186913B1 (en) | 2003-11-26 | 2016-02-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| US7781219B2 (en) | 2003-12-05 | 2010-08-24 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
| US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| EP1833766A1 (en) | 2004-12-17 | 2007-09-19 | Clearwater Systems Corp. | Method and apparatus for treating fluids |
| WO2006077265A1 (en) | 2005-01-24 | 2006-07-27 | F. Hoffmann-La Roche Ag | The use of bnp-type peptides and anp-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload |
| EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| US20070021977A1 (en) | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
| JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
| WO2007127749A2 (en) * | 2006-04-24 | 2007-11-08 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PL2021796T3 (pl) * | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| HUE025058T2 (en) | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
| US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
| WO2008116083A1 (en) | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2705500A1 (en) | 2007-05-11 | 2008-11-20 | Tufts Medical Center | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
| GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
| US20100267062A1 (en) | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
| FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
| HUE029880T2 (en) | 2008-04-18 | 2017-04-28 | Critical Care Diagnostics Inc | Predicting the risk of serious heart events |
| WO2010025393A2 (en) * | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
| JP5584695B2 (ja) | 2008-11-11 | 2014-09-03 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 |
| JP5728488B2 (ja) | 2009-11-13 | 2015-06-03 | ビージー メディシン， インコーポレイテッド | 心筋梗塞のリスクファクターおよび予測 |
| US8258456B2 (en) | 2009-11-27 | 2012-09-04 | Himax Imaging, Inc. | Image sensor |
| EP3434694B1 (en) | 2010-04-09 | 2020-12-30 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| RU2017110678A (ru) | 2010-11-01 | 2019-01-24 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
| RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| US8615387B2 (en) * | 2011-04-07 | 2013-12-24 | Invensys Systems, Inc. | Dynamic simulation of fluid filled vessels |
| EP2734222B1 (en) | 2011-07-18 | 2016-10-19 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| CN104507383B (zh) | 2012-05-18 | 2018-08-28 | 重症监护诊断股份有限公司 | 用于治疗或预报室性快速性心律失常事件风险的方法 |
| CN104737023B (zh) * | 2012-08-16 | 2017-07-28 | 重症监护诊断股份有限公司 | 预测患高血压风险的方法 |
| JP6450679B2 (ja) * | 2012-08-21 | 2019-01-09 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | マルチマーカーリスク層別化 |
| US9665593B2 (en) * | 2013-03-28 | 2017-05-30 | International Business Machines Corporation | Dynamically synching elements in file |
| JP6178687B2 (ja) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | グラビア塗工装置 |
| JP6655016B2 (ja) | 2014-01-10 | 2020-02-26 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心不全のリスクを決定するための方法 |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
| USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2009
- 2009-04-17 HU HUE14177846A patent/HUE029880T2/en unknown
- 2009-04-17 SI SI200931045T patent/SI2660599T1/sl unknown
- 2009-04-17 EP EP16166093.1A patent/EP3093663B1/en not_active Not-in-force
- 2009-04-17 ES ES14177846.4T patent/ES2590213T3/es active Active
- 2009-04-17 EP EP13179055.2A patent/EP2660599B1/en not_active Not-in-force
- 2009-04-17 SI SI200930776T patent/SI2269063T1/sl unknown
- 2009-04-17 EP EP09731842.2A patent/EP2269063B1/en not_active Not-in-force
- 2009-04-17 HR HRP20131100AT patent/HRP20131100T1/hr unknown
- 2009-04-17 PT PT141778464T patent/PT2827152T/pt unknown
- 2009-04-17 HU HUE16166093A patent/HUE039963T2/hu unknown
- 2009-04-17 PL PL16166093T patent/PL3093663T3/pl unknown
- 2009-04-17 ES ES16166093.1T patent/ES2687401T3/es active Active
- 2009-04-17 EP EP18166387.3A patent/EP3378955A1/en not_active Withdrawn
- 2009-04-17 JP JP2011505224A patent/JP5526122B2/ja not_active Expired - Fee Related
- 2009-04-17 EP EP14177846.4A patent/EP2827152B1/en not_active Not-in-force
- 2009-04-17 AU AU2009236109A patent/AU2009236109B2/en not_active Ceased
- 2009-04-17 DK DK09731842.2T patent/DK2269063T3/da active
- 2009-04-17 DK DK16166093.1T patent/DK3093663T3/en active
- 2009-04-17 WO PCT/US2009/040941 patent/WO2009129454A2/en not_active Ceased
- 2009-04-17 ES ES09731842.2T patent/ES2443125T3/es active Active
- 2009-04-17 PL PL14177846.4T patent/PL2827152T3/pl unknown
- 2009-04-17 PT PT131790552T patent/PT2660599E/pt unknown
- 2009-04-17 PT PT16166093T patent/PT3093663T/pt unknown
- 2009-04-17 DK DK14177846.4T patent/DK2827152T3/en active
- 2009-04-17 DK DK13179055.2T patent/DK2660599T3/en active
- 2009-04-17 US US12/425,956 patent/US8090562B2/en active Active
- 2009-04-17 ES ES13179055.2T patent/ES2525029T3/es active Active
- 2009-04-17 PT PT97318422T patent/PT2269063E/pt unknown
- 2009-04-17 SI SI200931872T patent/SI3093663T1/sl unknown
- 2009-04-17 PL PL09731842T patent/PL2269063T3/pl unknown
- 2009-04-17 SI SI200931469A patent/SI2827152T1/sl unknown
- 2009-04-17 PL PL13179055T patent/PL2660599T3/pl unknown
- 2009-04-17 CA CA2720674A patent/CA2720674A1/en not_active Abandoned
-
2011
- 2011-11-18 US US13/299,612 patent/US20120065897A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/787,137 patent/US9886553B2/en not_active Expired - Fee Related
-
2014
- 2014-04-03 US US14/244,526 patent/US9965593B2/en active Active
- 2014-04-14 JP JP2014082442A patent/JP5873521B2/ja not_active Expired - Fee Related
- 2014-11-03 HR HRP20141056AT patent/HRP20141056T1/hr unknown
-
2016
- 2016-01-15 JP JP2016006007A patent/JP6200975B2/ja not_active Expired - Fee Related
- 2016-02-04 AU AU2016200697A patent/AU2016200697B2/en not_active Ceased
-
2017
- 2017-08-28 JP JP2017162932A patent/JP6484679B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-04 AU AU2018202350A patent/AU2018202350A1/en not_active Abandoned
- 2018-04-12 US US15/951,376 patent/US11170896B2/en active Active
-
2019
- 2019-02-18 JP JP2019026401A patent/JP6788050B2/ja not_active Expired - Fee Related
-
2020
- 2020-10-29 JP JP2020181010A patent/JP2021039108A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520098A5 (enExample) | ||
| JP6484679B2 (ja) | 主要有害心イベントのリスクを予測する方法 | |
| JP2019105645A5 (enExample) | ||
| Adamopoulos et al. | Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy | |
| Chao et al. | The association between hyperuricemia, left atrial size and new-onset atrial fibrillation | |
| Gempp et al. | Reversible myocardial dysfunction and clinical outcome in scuba divers with immersion pulmonary edema | |
| JP7565291B2 (ja) | 消化管手術を受けた患者のｍａｃｃｅの診断方法 | |
| CN111500710B (zh) | circRNA730作为生物标志物在预测、诊断或预后脓毒症中的用途 | |
| Kievit et al. | Efficient selective screening for heart failure in elderly men and women from the community: A diagnostic individual participant data meta-analysis | |
| Chatzistamatiou et al. | Nocturnal hypertension: poor correlation with office blood pressure but strong prognostic factor for target organ damage | |
| Dinatolo et al. | Updates in heart failure: what last year brought to us | |
| Toyama et al. | Clinical significance of serum retinol binding protein‐4 levels in patients with systemic sclerosis | |
| Zoltowska et al. | Association between hypothyroidism and takotsubo cardiomyopathy: analysis of nationwide inpatient sample database | |
| Tang et al. | Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation? | |
| RU2566212C1 (ru) | Способ многофакторного прогнозирования отдаленных неблагоприятных исходов у пациентов, перенесших острый коронарный синдром со стойким подъемом сегмента st | |
| Rizzi et al. | Unfavorable donor pretransplant APACHE II, SAPS II, and SOFA scores are not associated with outcome: implications for heart transplant donor selection | |
| RU2014107752A (ru) | Среднерегиональный предшественник предсердного натрийуретического пептида (pro-anp) для идентификации пациентов с фибрилляцией предсердий, начавшейся меньше, чем 48 часов тому назад | |
| Vašků | Covid-19 infection and the host genetic predisposition: does it exist? | |
| JP2017534874A5 (enExample) | ||
| Vallejo-Vaz | Novel biomarkers in heart failure beyond natriuretic peptides—the case for soluble ST2 | |
| WO2012078502A3 (en) | Biomarker test for acute coronary syndrome | |
| Auffret et al. | Early and late ventricular arrhythmias complicating ST-segment elevation myocardial infarction | |
| RU2569458C1 (ru) | Способ диагностики хронической сердечной недостаточности путем использования циркулирующих уровней микрорнк | |
| Hermany et al. | Cardiac Biomarkers in Transcatheter Aortic Valve Implantation | |
| Kercheva et al. | Myocardial Infarction-Associated Shock: A Comprehensive Analysis of Phenotypes, SCAI Classification, and Outcome Assessment. |